Prostate Cancer
Improving Risk Stratification Among Veterans With Newly Diagnosed, Clinically Low-Risk Prostate Cancer Using the 17-Gene Genomic Prostate Score Assay.
Author(s): Julie Ann Lynch, et al.
Background: Active surveillance (AS) is a recommended treatment option for low risk prostate cancer (PCa). Studies have shown high rates of AS in the VA yet treatment variation exists between VAMCs, likely due to concern about missing aggressive disease. The 17-gene Genomic Prostate Score (GPS) has been validated to predict likelihood of favorable pathology in men with low risk PCa. This study compares treatment patterns before and after introduction of the GPS to determine if the assay assists in risk-stratification. Men with PCa who met National Comprehensive Cancer Network criteria for very low, low, or intermediate risk PCa were eligible. Chart review of men across 6 VAMCs established baseline treatment in untested patients in 2013-2014. In 2015, Veterans at the same VAMCs were offered the assay in a prospective study. Treatment recommendations and treatment implemented were captured.
To read the full abstract click here: http://meetinglibrary.asco.org/content/170703-176
Trends in Utilization of Novel Oral Therapeutic Agents for Men With Metastatic Castrate-Resistant Prostate Cancer Within the United States Veteran’s Affairs Health System.
Author(s): Elizabeth Henry, et al.
Background: Therapeutic options for men with metastatic castrate resistant prostate cancer (mCRPC) have expanded significantly over the past 5 years with several new agents demonstrating improved survival, including two oral agents. Abiraterone acetate, a CYP-17 androgen synthesis inhibitor, obtained initial FDA approval in 2011 for post-docetaxel (D) use, and gained expanded approval in 2012 for pre-D use. Enzalutamide, an androgen receptor signaling inhibitor, also gained FDA approval in 2012 (post-D) and indication was expanded in 2014 (pre-D). Due to the relatively recent approvals of these agents, there is limited data on rates of uptake and prescribing patterns for patients with mCRPC.
To read the full abstract click here: http://meetinglibrary.asco.org/content/157970-172
Liver
A Comparison of Liver Cancer Patients Receiving Palliative Care at Two Veteran Affairs Medical Centers.
Author(s): Sarah Lee, Zhen Wang, et al.
Background: Liver cancer is a leading cause of death. Lack of data exists on palliative care in this group, and care varies by location. The authors aim to determine if there are differences in palliative care for liver cancer patients by VA site.
To read the full abstract click here: http://meetinglibrary.asco.org/content/171726-176
[Click through for : Radiation Oncology, Lung Cancer, Colorectal, HIV and Cancer, Palliative Care, Esophageal]
